Evidence shows that compared to conventional radiotherapy, Stereotactic ablative radiotherapy can be effective when used to treat non-small cell lung cancer.

Evidence shows that SABR can be effective when used to treat non-small cell lung cancer however; there is less clinical evidence to show that SABR is effective for other cancers.
NHS England’s Commissioning through Evaluation program will increase the number of cancers being treated to include oligometastatic disease (cancer that has spread to another part of the body), primary liver tumors and the re-irradiation of cancers in the pelvis and spine.
Sean Duffy, National Clinical Director for Cancer at NHS England, said, “This program will allow us to assess this promising type of radiotherapy while enabling people who may benefit to access it as close to home as possible.”
Source-Medindia